Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: Suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model

Gene Therapy

Volumn 6, Issue 3, 1999, Pages 338-349

  Nasu, Y ^a   Bangma, C H ^a   Hull, G W ^a   Lee, H M ^a   Hu, J ^a   Wang, J ^a   McCurdy, M A ^a   Shimura, S ^a   Yang, G ^a   Timme, T L ^a   Thompson, T C ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Gene therapy; Interleukin 12; Metastasis; Orthotopic tumor model; Prostate cancer

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NITRIC OXIDE SYNTHASE;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL INFILTRATION; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; DOSE RESPONSE; ENZYME ACTIVITY; GENE THERAPY; GROWTH INHIBITION; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; INTRATUMORAL DRUG ADMINISTRATION; LUNG METASTASIS; MACROPHAGE; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; SURVIVAL TIME; TUMOR GROWTH;

ADENOVIRIDAE; ANIMALS; FLOW CYTOMETRY; GENE THERAPY; GENETIC VECTORS; IMMUNOHISTOCHEMISTRY; INJECTIONS, INTRALESIONAL; INTERLEUKIN-12; LUNG NEOPLASMS; MALE; MICE; NEOPLASM TRANSPLANTATION; PROSTATIC NEOPLASMS;

EID: 0032996037     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3300834     Document Type: Article

References (42)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1997. CA Cancer J Clin 1997; 47: 5-27.
2. Litwin MS et al. Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995; 273: 129-135.
3. Lu-Yao GL, McLarren D, Wasson J, Wennberg JE. An assessment of radical prostatectomy time trends, geographic variation and outcomes. The Prostate Patient Outcomes Research Team. JAMA 1993; 269: 2633-2636.
4. Eastham JA et al. In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 1995; 55: 5151-5155.
5. Eastham JA et al. Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by gancyclovir in mouse and human prostate cancer models. Hum Gene Ther 1996; 7: 515-523.
6. Hall SJ et al. Adenovirus-mediated herpes simplex virus thymidine kinase gene and gancyclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int J Cancer 1997; 70: 183-187.
7. Hall SJ et al. Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Ther (in press).
8. + GCV) for locally recurrent prostate cancer: absence of toxicity (Meeting abstract). Proc Annu Meet Am Soc Clin Oncol 1997; 16: A1577.
9. Vile RG et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 1994; 54: 6228-6234.
10. Barba D, Hardin J, Sadelain M, Gage FH. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994; 91: 4348-4352.
11. Felzman T, Ramsey WJ, Blaese RM. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenovirus expressing HSVtk, IL-12, II-6 or B7-1. Gene Therapy 1997; 4: 1322-1329.
12. Vile RG et al. Generation of an antitumor immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 1997; 71: 267-274.
13. Brunda MJ et al. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J Exp Med 1993; 178: 1223-1230.
14. Leonard JP et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-γ production. Blood 1997; 90: 2541-2548.
15. Caruso M et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996; 93: 11302-11306.
16. Rakhmilevich AL et al. Gene gun mediated skin transfection with interleukin-12 gene results in regression of established primary and metastatic murine tumors. Proc Natl Acad Sci USA 1996; 93: 6291-6296.
17. Tahara H et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995; 154: 6466-6674.
18. Tahara H, Lotze MT. Antitumor effects of interleukin-12 (IL-12): applications for the immunotherapy and gene therapy of cancer. Gene Therapy 1995; 2: 96-106.
19. Tahara H et al. IL-12 gene therapy using direct injection of tumors with genetically engineered autologous fibroblasts. Hum Gene Ther 1995; 6: 1607-1624.
20. Rakhmilevich AL et al. Cytokine gene therapy of cancer using gene gun technology: superior antitumor activity of interleukin-12. Hum Gene Ther 1997; 8: 1303-1311.
21. Bramson JL et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gene Ther 1996; 7: 1995-2002.
22. Thompson TC, Southgate J, Kitchner G, Land H. Multi-stage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 1989; 56: 917-930.
23. Baley PA et al. Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer. J Steroid Biochem 1995; 52: 403-413.
24. Sanda MG et al. Molecular characterization of defective antigen processing in human prostate cancer. J Natl Cancer Inst 1995; 87: 280-285
25. + cell-mediated immunity against rumors located in the 'immunologically privileged' central nervous system. Proc Natl Acad Sci USA 1996; 93: 10399-10404.
26. Fidler IJ, Naito S, Pathak S. Orthotopic implantation is essential for the selection, growth and metastasis of human renal cell cancer in nude mice. Cancer Metas Rev 1990; 9: 149-165.
27. Schmitt M et al. Involvement of T cell subsets and natural killer (NK) cells in the growth suppression of murine fibrosarcoma cells transfected with interleukin-12 (IL-12) genes. Int J Cancer 1997; 72: 505-511.
28. Nouri AM et al. Intensity of class I antigen expression on human tumour cell lines and its relevance to the efficiency of non-MHC-restricted killing. Br J Cancer 1993; 67: 1223-1228.
29. Geng YP et al. Expression of consensus type I interferon gene displays potent antitumor activity, induces MHC class I expression and enhances NK cell activity (Meeting abstract). J Cell Biochem 1995; 21: 421.
30. Cesano A, Visonneau S, Clark SC, Santoli D. Cellular and molecular mechanisms of activation of MHC nonrestricted cytotoxic cells by IL-12. J Immunol 1993; 151: 2943-2957.
31. Kasai M et al. A glycolipid on the surface of mouse natural killer cells. Eur J Immunol 1980; 10: 175-180.
32. Habu S et al. In vivo effects of anti-asialo GM1. I. Reduction of NK activity and enhancement of transplanted tumor growth in nude mice. Immunology 1981; 127: 34-38.
33. Kurzawa H et al. Recombinant interleukin-12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Res 1998; 58: 491-499.
34. α14 NKT cells in IL-12-mediated rejection of tumors. Science 1998; 278: 1623-1626.
35. + T cells on experimental haematogenous tumor metastases in the liver and lungs of mice. Immunology 1997; 92: 561-566.
36. Wigginton JM et al. Interleukin-12 primes macrophages for nitric oxide production in vivo and restores depressed nitric oxide production by macrophages from tumor-bearing mice: implications for the antitumor activity of interleukin 12 and/or interleukin 2. Cancer Res 1996; 56: 1131-1136.
37. Xie QW, Kashiwabara Y, Nathan C. Role of transcription factor NF-kappa B/Rel in induction of nitric oxide synthase. J Biol Chem 1994; 269: 4705-4708.
38. Voest EE et al. Inhibition of angiogenesis in vivo by interleukin-12. J Natl Cancer Inst 1995; 87: 581-586.
39. Bramson JL et al. Construction of double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Ther 1996; 7: 333-342.
40. Wang J, Bucana CD, Roth JA, Zhang WW. Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 1995; 2: 9-17.
41. Tan J et al. Injection of complementary DNA encoding interleukin-12 inhibits tumor establishment at a distant site in a murine renal carcinoma model. Cancer Res 1996; 56: 3399-3403.
42. Yang G, Timme, TL, Park S-H, Thompson TC. Transforming growth factor β1 transduced mouse prostate reconstitutions: I. Induction of neuronal phenotypes. Prostate 1997; 33: 1521-1526.